Shanghai Leadingtac Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a pan-KRAS-targeting moiety through a linker.
Petra Pharma Corp. has identified phosphatidylinositol 3-kinase α (PI3Kα) E545K and H1047R mutant inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum (PROS).
Aligos Therapeutics Inc. and Katholieke Universiteit Leuven (KU Leuken) have synthesized antiviral compounds reported to be useful for the treatment of coronavirus acute respiratory syndrome, norovirus and picornavirus infections.
Scientists at Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Medicine Co. Ltd. have disclosed norbornene derivatives reported to be useful for the treatment of cerebral infarction, coronary heart disease, myocardial infarction and cerebral ischemia.
Researchers from Macrogenics Inc. presented preclinical efficacy data on MGC-026, an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody (MGA017) targeting B7-H3, linked to a cytotoxic exatecan payload via a cleavable Val-Ala-PABC linker using Synaffix Glycoconnect technology.
Taxanes such as paclitaxel are among the standard chemotherapies for triple-negative breast cancer, one of the most aggressive forms of this tumor type. However, numerous processes can contribute to paclitaxel resistance. As a next-generation drug that could help overcome such resistance, researchers at six universities in China, including Ningxia Medical University, examined the crystal structure of protein arginine methyltransferase 1 (PRMT1) and developed, in silico, a pharmacophore that could bind tightly to it. PRMT1, which acts as an epigenetic regulator, is overexpressed in various cancers and its levels correlate inversely with survival.
Researchers from Chemdiv Inc. and Eilean Therapeutics LLC recently presented preclinical data on ZE77-0273, an AI-designed, reversible pan-EGFR inhibitor developed to address a key unmet need in the treatment of EGFR-mutant non-small-cell lung cancer.
Prospect Therapeutics Inc.’s PSTA-2413 is a newly developed oral pan-RAS inhibitor that demonstrates selectivity over wild-type KRAS, along with strong in vitro potency and in vivo antitumor efficacy.
The Schlafen (SLFN) family of interferon-inducible genes, involved in the regulation of immune and antiviral responses, has recently attracted attention for the development of novel anticancer therapies.
RSS
